Tourette's Syndrome
Condition Description
A nervous system disorder involving repetitive movements or unwanted sounds.
Tourette syndrome starts in childhood.
It involves uncontrollable repetitive movements or unwanted sounds (tics), such as repeatedly blinking the eyes, shrugging shoulders, or blurting out offensive words.
Active Trials
-
TRIAL TITLE: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Maintenance of Efficacy of Ecopipam in Children, Adolescents and Adults with Tourette’s Disorder.
DESCRIPTION: This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD). The study includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.
SPONSOR: Emalex Biosciences, Inc.
INDICATION: Tourette’s Syndrome
STUDY PROTOCOL: EBS-101-TD-301
PHASE: 3
STATUS: Active
RECRUITING PATIENTS: Yes
Upcoming Trials
Past Trials
-
TRIAL TITLE: A Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome
DESCRIPTION: This study evaluates the effect of ecopipam tablets in children and adolescents in the treatment of Tourette's Syndrome (TS). Half of the participants will receive ecopipam tablets, while the other half will receive matching placebo tablets.
SPONSOR: Emalex Biosciences, Inc.
INDICATION: Tourette’s Syndrome
STUDY PROTOCOL: EBS-101-CL-001
PHASE: 2b
STATUS: Completed
RECRUITING PATIENTS: No
-
TRIAL TITLE: A Multicenter, Open-Label, Extension Study Intended to Evaluate the Long-term Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome.
DESCRIPTION: his study was an international, multicenter, open-label, long term extension study evaluating the safety of ecopipam tablets for the treatment of children and adolescent subjects with Tourette Syndrome.
SPONSOR: Emalex Biosciences, Inc.
INDICATION: Tourette’s Syndrome
STUDY PROTOCOL: EBS-101-CL-001
PHASE: 2b
STATUS: Completed
RECRUITING PATIENTS: No